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Abstract
Background: To evaluate the efficacy, safety, pain perception and health-related quality of life (QoL) of percutaneous
ethanol injection treatment (PEIT) as an alternative to thyroid surgery in symptomatic thyroid cysts.
Methods: Thirty consecutive patients (46 ± 10 years; 82 % women) with symptomatic benign thyroid cysts relapsed
after drainage were included. In all cases, cytology prior to treatment, maximum cyst diameter and volume were
determined. PEIT was conducted using the established procedure, and the volume of fluid removed and pain
perceived by the patient were assessed. In each procedure, the volume of alcohol instilled was <2 ml. After follow-up,
final cyst diameter and volume were determined and the persistence of symptoms and QoL were assessed by a
questionnaire (SF-36).
Results: Mean symptom duration was 10 ± 20 months. A single session of PEIT was required to complete the procedure
in 45 % of patients, two in 31 % and three in 13 %. Mean initial maximum cyst diameter was 3.5 ± 1.0 cm and mean
extracted liquid volume 61 ± 36 ml. During PEIT, 39 % of patients experienced virtually no pain, 43 % mild pain and 17 %
moderate pain. No complications of PEIT were observed. After 12.1 ± 1.4 months of follow-up, cysts were reduced more
than 70 % in volume in 86.3 % of patients, more than 80 % in 61.9 % and more than 90 % in 42 %. On the health-related
QoL SF-36 questionnaire, patient scores 6 months post-PEIT did not differ significantly from those of the healthy Spanish
population. With respect to cosmetic complaints or local symptoms of compression, PEIT-treated patients presented an
initial score of 22 ± 8 and 13 ± 5 after treatment (p < 0.05).
Conclusions: In our experience, percutaneous ethanol injection has prove to be an effective, safe and well-tolerated first-
line treatment of symptomatic thyroid cysts.
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Background
Thyroid nodules are common in the general population
with a prevalence of palpable lesions between 3 and 10 %
[1]. Moreover, non-palpable ultrasound-detected thyroid
nodules are present in 20 to 60 % of healthy individuals [2].
Thyroid cysts are characterised by their liquid contents and
are mostly benign [3]. After percutaneous drainage, most
cystic lesions (around 80 %) refill and enlarge over time. In
cases of recurrent thyroid cysts producing aesthetic com-
plaints or compressive symptoms, surgery has been the
first-line treatment to date [4]. Since the late 1990s,
sonography-guided percutaneous ethanol injection treat-
ment (PEIT) has emerged as a safe and effective conserva-
tive alternative to surgical excision [5]. The injection of
95–99 % ethanol into the cyst cavity induces thrombosis of
small vessels and coagulative necrosis surrounded by inter-
stitial oedema and granulomatous inflammation, followed
by fibrosis, shrinkage and reduction in the volume of the
lesion [5, 6]. A randomised study from Bennedbaek and
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Hegedüs reported a significant 82 % volume reduction in
the PEIT group (n = 33) compared to 18 % in the saline
treated group (n = 33) [7], with few complications, thereby
providing data permitting this technique to be considered
as a reliable alternative to thyroid surgery. In this respect,
recent guidelines in the USA and Europe [2] state that
PEIT is a clinically-effective, non-surgical option for repeat-
edly drained recurrent thyroid cysts. However, there is a
paucity of reports in the literature from few centres de-
scribing the outcomes of this technique for avoiding sur-
gery in these patients when it is introduced in systematic
clinical practice.
Furthermore, as a recent review of the Cochrane Col-
laboration established, previous studies on this tech-
nique did not provide information on health-related
quality of life (QoL) and the authors of the review thus
suggested that this important measure for the patient
should also be a primary end-point in future trials. [8].
Herein, we reported our results on effectiveness, safety,
pain perception and health-related QoL in a group of pa-
tients with symptomatic recurrent thyroid cysts after PEIT.
Methods
Thirty consecutive patients treated at the outpatient clinic
of the Endocrinology and Nutrition Department of the Ger-
mans Trias i Pujol Universtity Hospital, Badalona, in 2013
and referred for evaluation of a cervical nodule or nodular
goiter were included. A case was considered for PEIT if it
met all the following selection criteria: 1) age >18 years; 2)
normal thyroid function tests; 3) no major comorbidities; 4)
no history of neck irradiation; 5) cystic or predominantly
cystic (>80 % cystic component) thyroid nodule; 6) com-
pressive symptoms or aesthetic complaints; and 7) volun-
tary patient decision to undergo PEIT instead of open
surgery after careful explanation of the procedure. The
study was conducted in accordance with the Declaration of
Helsinki and was approved by the local Human Research
Ethics Committee of the Hospital Germans Trias i Pujol.
All participants gave their written informed consent.
In all cases, a medical history was taken and physical
examination performed and blood samples were obtained
for analytical determinations. Serum free thyroxine (fT4)
and TSH were measured by electrochemiluminescence
immunoassay (Siemens©, Los Angeles, CA, USA).
Ultrasound examination
An echography examination was performed in each pa-
tient by an experienced operator (JLR) using a 12–
15 MHz linear transducer device. Morphological evalu-
ation included description of the thyroid echostructure
and measurement of the diameters and ultrasound char-
acteristics of each detected nodule (Fig. 1, panel a).
Volumetric assessment of the nodules was based on the
use of an ellipsoid model [9]. With this rotating ellipsoid
model, the height, width and depth of each nodule were
measured and multiplied. The obtained result was then
multiplied by the mathematical constant or correction
factor 0.524 [10]. Fine-needle aspiration (FNA) cytology
was performed in all cases to obtain samples from all
nodules >1.0 cm in diameter and those between 0.5 and
1.0 cm if they presented suspicious ultrasound charac-
teristics according to the American Society of Ultrason-
ography [11] such as the presence of microcalcifications,
irregular borders, increased central flow on Doppler
examination, taller than wide diameter, hypoechogenicity
and absence of halo. In the case of cysts, FNA was per-
formed from the capsule or solid part of the nodule and
for drainage of the cyst contents, and cytological analysis
was performed. Patients were offered PEIT if the cyst
presented significant regrowth after the first drainage
with compressive symptoms or aesthetic complaints and
cytological analysis was benign and preferred not to
undergo thyroid surgery after extensive explanation of
the procedure.
Percutaneous ethanol injection treatment procedure
Positions of the patient and operator were similar to
those of the FNA procedure, with the patient lying with
their neck in hyperextension. After skin sterilisation, and
Fig. 1 Transverse ultrasound scans of one cyst before (panel a), during (panel b) and after (panel c) percutaneous ethanol injection treatment
(PEIT). During PEIT, cystic lumen was filled with instilled ethanol (arrow). Panel c shows marked decrease in size
Reverter et al. BMC Endocrine Disorders  (2015) 15:73 Page 2 of 6
under ultrasound guidance, a 21 G needle mounted on a
connector with a line extension and a 20 ml syringe
were used to empty the contents of the cyst. Subse-
quently, 0.5 ml of 5 % lidocaine was infused into the cyst
cavity and, after a 2 min wait, 99 % ethanol was injected
with a slow movement of the needle to reach the major
part of the inner face of the cyst capsule (Figure 1, panel b).
The patient was instructed to signal any feeling of pain to
prevent the spread of alcohol into the neck structures. The
amount of ethanol injected was 50 % of the volume of li-
quid extracted with a maximum of 2 ml. The needle tip
was constantly visualsed during the procedure. In no
case were more than 2 ml injected. The ethanol was not
re-extracted and patients were discharged after a 20–30-
minute observation period.
Follow-up
Patients were followed up weekly for 1 month, monthly
for 3 months and every 3 months thereafter. Ultrasound
examination was performed at each appointment to
evaluate the characteristics and volume of the residual
lesion (Fig. 1, panel c).
In cases of symptomatic cyst regrowth confirmed by
echography, a new PEIT was performed with the same
protocol followed by weekly appointments. This proced-
ure was repeated until permanent and significant cyst re-
duction was achieved or the patient decided not to
repeat the PEIT procedure. No limits were set in the
number of PEIT procedures.
Response parameters
In each patient, the percentage of volume reduction was
calculated by the formula [(V1 −V2)/V1] × 100 in which
V1 is the initial cyst volume and V2 the final cyst
volume.
Patients were requested to grade the sensation of pain
suffered with the alcohol injection immediately after the
procedure, using a visual scale of 10 cm between the ab-
sence of pain (0) and excruciating pain (10) in which
each 1/3 of the scale corresponded, from the lowest to
the highest, to the following categories: mild pain, mod-
erate pain and severe pain.
Health-related quality of life
The Spanish version of the SF-36 questionnaire provided
online by www.sf-36.org/ was administered to each pa-
tient 6 months after the last PEIT. The SF-36 question-
naire is a multipurpose, short-form health survey,
commonly used to evaluate patients’ health-related QoL
in clinical practice. Eight domains are assessed in this
questionnaire, including physical functioning, role limi-
tation due to physical problems, bodily pain, general
health, vitality, social functioning, role limitation due to
emotional problem, and mental health. The eight health
domains were used to provide a physical component
summary (PCS) and a mental component summary
score (MCS). Interpretation of the SF-36 Health Survey
was greatly simplified with the norm-based scoring
(NBS) of its health domain scales and component sum-
mary measures. In NBS, each scale is scored to have the
same average (50) and the same standard deviation [10],
signifying that each point equals one-tenth of a standard
deviation [12]. For all scales and summary measures
mean group scores below 47 can be interpreted as being
below the average range for the general population.
With a view to assessing the specific symptoms of
neck cysts derived, we created a domestic non-validated
questionnaire including ten items related to the most
frequent goitre symptoms described in the literature.
These symptoms were related to visible enlargement of
the neck (cosmetic complaint), feeling of pressure in the
neck, throat pressure, sore throat, pain in the throat ra-
diating to the ears, difficulty in swallowing, throat clear-
ing often, shortness of breath and hoarseness. Each item
was scored between 1 (none of the time), 2 (a little of
the time), 3 (some of the time), 4 (most of the time) and
5 (all of the time), and the final score was the sum of the
ten items. Thus, a score could range from ten (absence
of symptoms) to 50 (patient’s worst feeling of symp-
toms). Compressive symptoms on the trachea were eval-
uated by chest X-ray.
Statistical analysis
Continuous variables were expressed as mean ± SD or
median (interquartile range) and categorical variables as
percentages. Student’s t-test was used for comparisons
between continuous variables and Pearson’s correl-
ation test for correlation analyses. A p value < 0.05 was
considered statistically significant and correlations were
considered significant for Pearson’s correlation coefficient
if ≥0.25. For comparison of categorical variables, the chi-
square test or Fisher’s exact test were used where appro-
priate. Data analyses were made using the Statistical Pack-
age for Social Sciences (SPSS©, Chicago, IL, USA) for
Windows®, Version 15.0.
Results and discussion
Thirty subjects with symptomatic thyroid cysts (46 ±
10 years; 82 % women) were included in the protocol.
Mean duration of symptoms was 10 (1–36) months and,
in all cases, TSH and fT4 were within the normal range.
FNA cytology was benign in all samples obtained (haem-
orrhagic-cystic lesion, colloid cyst or non-malignant le-
sion) from the predominantly cystic nodules and the
other nodules with sonographic criteria for FNA cy-
tology [13]. Mean maximum cyst diameter before drain-
age was 3.5 ± 1.0 cm with a calculated initial volume of
18.2 ± 15.5 ml (median 14.5 ml). Mean total volume
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extracted from the cysts in all procedures performed
was 61.0 ± 36.5 ml (2–265 ml).
The required number of PEIT for permanent reduc-
tion in cysts and a symptom-free situation was one in
45.5 % of cases, two in 31.8 % and three in 13.6 %. Two
patients with the largest cysts in this series (total volume
extracted: 145 and 265 ml) were treated four and six
times, respectively. Initial calculated cyst volume was
significantly greater in the group of patients who re-
quired three or more PEIT procedures compared with
those treated with one or two PEITs (29.6 ± 25.5 ml vs.
15.5 ± 10.6 ml, respectively; p < 0.05).
In all cases requiring more than one treatment, cyst
recurrence was observed during the first month post-
treatment, both for the first PEIT and subsequent proce-
dures. No delayed recurrences were observed.
The sensation of pain reported during PEIT was virtu-
ally absent (39.1 %), mild (43.5 %) or moderate (17.4 %).
In all cases, this was a transient sensation of pain with
relief within minutes. No patient felt intense pain and
none suffered other complications.
After 12.1 ± 1.4 months of follow-up mean calculated
cyst volume reduction was 85.9 ± 14.7 %. In all cases,
cyst volume was reduced more than 50 % from the basal.
Cysts were reduced more than 70 % in volume in 86.3 %
of patients, more than 80 % in 61.9 % and more than
90 % in 42 %. Final mean maximum thyroid cysts diam-
eter was 1.3 ± 0.6 cm. Total disappearance of the cysts
was observed in three cases.
Regarding the characteristics of cystic lesions, 19 of
the cysts were purely cystic nodules, and 11 mixed or
predominantly cystic nodules (with a <20 solid compo-
nent). No differences were observed between cystic and
mixed nodules in calculated baseline volume (19.7 ± 16.1
vs 14.8 ± 8.7 ml, respectively; p = 0.3), calculated final
volume (1.6 ± 2.6 vs. 1.9 ± 1.6 ml, respectively; p = 0.7)
and volume reduction (88.2 ± 12 vs. 80.3 ± 17.5 % re-
spectively; p = 0.2). The number of PEIT sessions re-
quired was also similar (one in 47.3 vs. 50.0 %, p = 0.8; in
purely cystic and mixed cysts, respectively).
Table 1 summarizes the final volume observed and the
volume reduction according to the calculated initial volume
of the cysts. No significant differences were observed be-
tween cysts >15 ml in the calculated final volume (p = 0.7).
As expected, volume reduction was significantly (p = 0.002)
greater in nodules >15 ml (78.1 ± 15.8 %) compared to
those <15 ml (93.7 ± 7.5 %), p = 0.002.
In the health-related QoL SF-36 questionnaire, norm-
based PCS [52.4 (4.4)] and MCS [49.3 (4.8)] scores of
the patients 6 months after PEIT did not significantly
differ from those of the healthy Spanish population [14].
With respect to specific questions addressing to cos-
metic complaints or local symptoms of compression,
PEIT-treated patients presented an initial score of 22 ± 8
and after treatment 13 ± 5 (p < 0.05) with 47 % of cases
reporting a score of ten, i.e. absence of symptoms.
In the correlation analysis, a significant relationship
observed were between calculated initial cyst volume
and evolution time (r = −0.4, p = 0.02) and between base-
line calculated volume and volume reduction (r = −0.1,
p = 0.04).
Discussion
In our experience, percutaneous ethanol treatment is a
safe, well-tolerated and effective procedure for the treat-
ment of symptomatic benign thyroid cysts, achieving relief
or the disappearance of the aesthetical complaints and/or
compressive symptoms in all treated patients. Moreover,
patients who underwent this technique showed a health-
related quality of life related similar that of the normal
population according to a validated questionnaire.
Since the introduction of PEIT for thyroid cysts in clin-
ical practice, some groups from Italy [15–18], Denmark
[7] and South Korea [19, 20] reported a significant high
success rate (more than 80 %) with no significant side ef-
fects. Based on these results, the major endocrine society
guidelines state that treatment of recurrent benign thyroid
cysts with ethanol in experienced hands is a clinically ef-
fective, non-surgical option for purely or predominantly
cystic thyroid nodules that recur after repeat aspirations
[2, 21]. The results obtained in our group of treated pa-
tients after the PEIT procedure was introduced as a regu-
lar practice at our hospital concur with those good results
report in terms of efficacy and safety, with more than
70 % volume reduction in more than 85 % of patients and
the disappearance of aesthetic complaints or compression
in almost half of cases and significant relief in the rest.
In our protocol, we offered PEIT after the first cyst
drainage. With this approach, the benign nature of the
lesion was confirmed by cytological examination of the
samples and the refilling of cysts that occurred in all
cases in this series. The number of PEIT sessions re-
quired ranged from one to six depending on initial cyst
size and volume. However, the majority of cases (87.3 %
in our series) were resolved with the first or second pro-
cedure and whether more than two treatments were re-
quired depended on initial cyst volume. In our opinion
Table 1 Cyst volume results
<15 ml (n = 15) >15 ml (n = 15) P value
Baseline volume (ml) 8.4 ± 4.1 28.8 ± 13.1 0.001
Final volume (ml) 1.6 ± 1.5 1.9 ± 2.9 0.7
Volume reduction (%) 78.1 ± 15.8 93.7 ± 7.5 0.002
Results on calculated cyst volume and percentage of volume reduction in
patients treated with percutaneous ethanol injection treatment (PEIT)
according to their initial volume
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this feature is important in order to discuss with the pa-
tient before the procedure the eventual needing of more
than one or two PEITs.
The volume of ethanol used in PEIT is a matter of de-
bate. The reported amounts of ethanol administered ranged
from 35 to 100 mL depending on the authors [6, 7, 16, 19],
with a recommended maximum single infusion of 10 mL,
although treatments with the instillation of up to 30 mL
have been reported [22]. In our protocol, we decided to use
a maximum ethanol volume of less than 2 mL in all cases.
We, like others [23], believe this cautious approach offers
several advantages such as less pain, and lower risk of etha-
nol leakage into surrounding tissues and, owing to collapse
of the cyst after drainage of its liquid content, this small
amount of ethanol is sufficient to contact with the wall
without dilution. On the other hand, we decided not to
re-aspirate the ethanol after it was instilled into the empty
cyst cavity. Previous studies reported similar results in the
non-re-aspiration and re-aspiration groups [22]; however,
the non-re-aspiration technique is less time consuming
and reduces the number of injections in each patient, and
minimizes the possibility of the needle protruding from
the cyst cavity due to longer handling during the re-
aspiration phase of the procedure. The efficacy of the pro-
cedure in reducing of cyst volume and symptoms in the
present study supports this approach.
A major concern in all interventional procedures is pa-
tient comfort. We specifically tested pain sensation during
PEIT using a visual scale, and it is noteworthy that over
80 % of patients reported virtually absent or mild pain and
none of the treated group subjects described it as greater
than moderate. Previous reports described a transient
mild or burning sensation, which was more intense in the
largest cysts [7, 24]. Based on these results no local anaes-
thesia is usually recommended. In our protocol, the injec-
tion of a small amount of lidocaine into the cyst cavity
before ethanol instillation was included. The high rate of
patients reporting virtually no pain (almost 40 %) supports
continuing with this procedure.
There is a lack of information in the literature re-
garding the quality of life of patients with recurrent
thyroid cysts treated with ethanol [8]. We addressed
this question using a general health questionnaire (SF
36) and a specific questionnaire for symptoms of
goitre, we detected normal health quality status as
reflected in the SF-36 results and a significant im-
provement in goitre symptoms using the specific
questionnaire. We tested general health only after
performing PEIT since, in thyroid nodules with no as-
sociated hypo- or hyperthyroidism, the main com-
plaint is local neck symptoms. Post-treatment
evaluation confirmed that the procedure did not
affect the patient well-being, which therefore had to
be similar to that of the general population in terms
of SF-36 score. A summary of physical and mental
scores showed good status in these patients compared
the normal population. Moreover, the specific symp-
toms of goitre improved dramatically until its dis-
appearance in many patients. To our knowledge, no
previous studies had been conducted on QoL in pa-
tients with ethanol-treated thyroid cysts and our
results add new data in favour of PEIT as an alterna-
tive to thyroid surgery. The American and European
guidelines [2, 21] recommend PEIT for thyroid cysts,
but only those that recur after repeated aspirations. Based
on our results and previous reports [6, 7, 16, 19, 22, 23],
we believe PEIT should be included as the treatment of
choice after the first unsuccessful drainage of cysts. Al-
though the protocol for PEIT is not universally unified re-
garding the amount of alcohol instilled, re-aspiration of
the instilled ethanol and the different use of anaesthesia
according to groups, the general results obtained by PEIT
are not affected by these protocol differences. Thus,
albeit not mandatory, it would be convenient to have
a homogeneous protocol established by scientific soci-
eties and ad hoc guidelines based on the reported
results and local experience [25, 26].
Conclusions
PEIT in recurrent thyroid cysts appears to be a highly ef-
ficacious and safe technique. The improvement in clin-
ical conditions obtained with very low pain sensation,
absence of complications and good QoL perceived after
the procedure render PEIT an optimum and more rec-
ommendable alternative to thyroid surgery. In our opin-
ion, future guidelines should include PEIT prior to
surgical treatment and establish a uniform consensus
protocol.
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